胸痛影像学评估的前瞻性多中心研究及进展

胸痛评估的前瞻性多中心影像学研究（PROMISE）始于2010年,该研究分析症状稳定的疑似冠心病病人首选冠状动脉CT血管成像（CCTA）进行解剖学检查或首选无创性功能学检查,旨在探究病人临床结局的差异。PROMISE研究了CCTA、功能学检查及冠状动脉钙化积分和CT血流储备分数等无创性检查方法对疑似冠心病的稳定性胸痛病人的预后价值,并探讨了生物标志物、年龄、性别、代谢性疾病对稳定性胸痛病人的影响。此外,PROMISE开发并验证了风险分层模型和个体化选择检查方法的工具。PROMISE对CCTA和功能学检查的应用产生了很大的影响,为疑似冠心病病人无创检查方法的选择提供了重要循证依据。     

Experimental reconstruction of dog's esophagus with biotype artificial esophagus

OBJECTIVE: At present, there are few materials available for esophagus reconstruction anywhere in the world. The reported survival rate in animals during the perioperative period is comparatively low. The present study assessed the feasibility of using a biotype artificial esophagus in the reconstruction of a dog's esophagus. METHODS: In 30 mongrel dogs, a portion of the thoracic esophagus was resected and an 8 cm section of artificial esophagus was transplanted to reconstruct the organ. The survival rate, food intake and process of healing were observed. RESULTS: Of the 30 dogs, 28 survived the peri­operative period (93.3% survival). Two dogs (6.7%) developed an anastomotic fistula; 19 dogs survived for 1 year, a survival rate of 79.2% (19/24) with the remaining six dogs were killed according to the experimental protocol. Detachment of the artificial esophagus occurred on average 28.8 days after operation and the dogs suffered from varying degrees of dysphagia 23?45 days after operation. Gradual remission occurred after 4 months. The histological study revealed that the regenerated esophagus was composed of fibrous and connective tissues and the luminal surface was covered with squamous epithelium in 3?6 months. CONCLUSION: The transplanted artificial esophagus detached after the surrounding ‘regenerated esophagus’ had formed, and the squamous epithelium gradually covered the luminal surface. Continuous remodeling of the ‘regenerated esophagus’ gradually relieved the stenosis. Whether detachment of the implant and the postoperative stenosis can be solved is the key problem restricting the use of the biotype artificial esophagus in clinical practice.     

结核分枝杆菌分泌蛋白Ag85B-ESAT6的融合表达及纯化

目的　融合表达结核分枝杆菌分泌蛋白Ag85B ESAT6 ,为结核病的预防提供有效亚单位疫苗。方法　设计含不同酶切位点的Ag85B和ESAT6引物 ,采用聚合酶链反应 (polymerasechainreaction ,PCR)的方法从结核分枝杆菌毒株H3 7Rv DNA中分别扩增出相应大小的DNA片段 ,将片段分别与PGEM T easy载体连接测序。将测序正确的Ag85B和ESAT6按照不同的酶切位点克隆入PPROEXHT表达载体 ,挑选出阳性克隆 ,将诱导的表达产物进行聚丙烯酰胺凝胶电泳 (SDS PAGE)分析 ,同时与含6个组氨酸 (histidine 6×his)的单克隆抗体 (monoclonalantibody ,mAb)进行固定化蛋白质免疫学测定(Western blot) ,将用含Ni 鳌合剂的Ni NTA亲合柱纯化的表达产物免疫小鼠 ,用结核分枝杆菌培养上清滤液蛋白 (culturefiltrateproteins ,CFP)作为抗原 ,酶联免疫吸附试验 (enzyme linkedimmunosorbentassay ,ELISA)测定免疫小鼠血清特异性抗体的滴度。结果　PCR获得的Ag85B和ESAT6序列与基因文库 (GenBank)报道的完全一致。两者在大肠杆菌DH5α株中融合表达的产物约为 370 0 0 ,与预计大小相吻合。Western blot结果显示 ,在相对分子量约 370 0 0处有表达产物与 6×hismAb特异性结合带。表达产物为包涵体 ,通过Ni NTA纯化系统 ,可得到纯化的目的蛋白。Ag8     

Genes in one megabase of the HLA class I region.

To define the gene content of the HLA class I region, cDNA selection was applied to three overlapping yeast artificial chromosomes (YACs) that spanned 1 megabase (Mb) of this region of the human major histocompatibility complex. These YACs extended from the region centromeric to HLA-E to the region telomeric to HLA-F. In addition to the recognized class I genes and pseudogenes and the anonymous non-class-I genes described recently by us and others, 20 additional anonymous cDNA clones were identified from this 1-Mb region. We also identified a long repetitive DNA element in the region between HLA-B and HLA-E. Homologues of this element were located at several sites in the human genome outside of the HLA complex. The portion of the HLA class I region represented by these YACs shows an average gene density as high as the class II and class III regions. Thus, the high gene density portion of the HLA complex is extended to more than 3 Mb.     

未接受抗病毒治疗的慢性乙型肝炎患者多聚酶P基因YMDD变异检测

目的 了解未经拉米夫定及干扰素抗病毒治疗的慢性乙型肝炎患者中HBV多聚酶YMDD变异情况。方法 应用错配PCR扩增方法检测病人血清HBV的YMDD位点，选择65例病史超过半年以上、肝功能异常、HBV DNA阳性的慢性乙型肝炎患者。结果 在65例患者中，YMDD变异阳性6例(9．07％)，阴性59例，6例变异中2例为YIDD阳性，其中1例为YMDD野毒株和变异株混合存在，4例为YYDD阳性，其中1例为YMDD野毒株和变异株混合存在。结论 本检测方法简便、实用，在未经抗病毒治疗的慢性乙型肝炎患者中可存在YMDD变异株，其与野生株一样是自然存在的。     

Acute lymphoblastic leukemia of childhood: identification of two distinct regions of deletion on the short arm of chromosome 12 in the region of TEL and KIP1

Cytogenetic analysis of acute lymphoblastic leukemia (ALL) of childhood identified nonrandom chromosomal abnormalities of the short arm of chromosome 12. The alterations include deletions that are thought to be indicative of the presence of a tumor suppressor gene that is mutated on the remaining allele. To refine further the chromosomal localization of this gene, we analyzed the loss of heterozygosity (LOH) of chromosome 12 in 100 primary ALL samples using 22 polymorphic markers and identified two distinct smallest common deleted regions on chromosome 12p13. One region is flanked by D12S77 and D12S98 and has a size of 4 cM. Twenty-six percent of informative patients showed LOH in this region. This region may contain the TEL gene. The other region is flanked by D12S269 and D12S308 including the KIP1 gene. Forty-four percent of informative patients showed LOH in this second region. Mutational analysis of KIP1 using polymerase chain reaction-single- strand conformation polymorphism analysis and Southern blot analysis showed no homozygous deletions and point mutations suggesting that the altered gene in this second region is not the KIP1. Clinical data showed that LOH of 12p was demonstrated more frequently in precursor-B ALLs (32 of 80; 40%) than in T-ALLs (1 of 20; 5%) (P = .0027). Furthermore, patients with 12p LOH were younger (P = .013), with a lower DNA index (P = .046), but they had the same survival rates at 3 years. In summary, these data suggest that two different tumor suppressor genes are on chromosome arm 12p, which act separately in the development of childhood precursor-B ALLs. One of the tumor suppressor genes is in the region the KIP1 gene, but our data suggest this gene is not abnormal. The other target is in the region of the TEL gene; and this candidate deserves further study.     

肾上腺素能β2受体基因多态性与慢性心力衰竭关系的研究

目的:在上海地区汉族人群中研究肾上腺素能β2受体(β2受体)基因多态性与慢性心力衰竭(心衰)的关系.方法:选取92例慢性心衰患者(心衰组)和80例健康人(正常对照组),进行外周静脉血的脱氧核糖核酸(DNA)抽提,通过多聚酶链式反应扩增后,进行β2受体基因的测序.结果:发现β2受体基因有4个多态性位点,分别为:16 Arg/Gly、27 Gln/Glu、87 Leu A/G、178 ArgA/C.其中27Gln/Glu位点在正常对照组中全部表现为C/C基因型,而在心衰组中有7例表现为G/C基因型,没有发现G/G基因型,两组间基因型和等位基因型的差异均有极显著的统计学意义(P＜0.01),而其它多态性位点两组间比较差异均无统计学意义(P＞0.05).结论:在上海地区汉族人群中β2受体基因多态性与心衰密切相关,其中27 Gln/Glu杂合子可能为心衰的易感基因,并且与心衰的严重程度、左心室收缩功能密切相关.     

幽门螺杆菌感染对胃黏膜病理变化的影响

背景：幽门螺杆菌(H．pylori)感染已被公认为慢性胃炎和消化性溃疡的重要危险因素，根除H．pylori能加速消化性溃疡的愈合，但其对胃黏膜病理变化的影响尚有待进一步探索。目的：了解根除H．pylori对慢性胃炎胃黏膜病理变化和癌前状态的影响。方法：采用多中心随机对照临床试验和回顾性队列研究，样本选自胃癌高发区：上海郊区的金山区和奉贤区。共纳入360例经内镜检查证实有H．pylori感染的慢性胃炎伴或不伴十二指肠溃疡患者，随机分为两组。治疗组用三联疗法(质子泵抑制剂或Hz受体阻滞剂加两种抗生素)治疗，对照组单纯慢性胃炎患者予西沙必利、十二指肠溃疡患者予西米替丁治疗。在第1年和第4年末随访胃镜，根据H．pylori是否根除将患者分为两组：H．pylori阳性组和H．pylori阴性组。所有胃黏膜活检标本由两位病理科医师统一复读。结果：至第4年末，有120例患者完成全部随访，其中H．pylori持续根除组54例，阳转组5例；H．pylori持续未根除组45例，阴转组16例。持续根除组第1年随访时，活动性炎症比例减少(P＜O．05)；第4年随访时，慢性炎症和肠化程度以及活动性炎症比例减少(P＜O．05)。持续未根除组第1年随访时，慢性炎症程度增加(P＜O．05)；第4年随访时，慢性炎症和肠化程度以及活动性炎症比例增加(P＜O．05)，萎缩程度较第1年随访时增加(P＜O．05)。结论：根除H．pylori可以减轻慢性胃炎的炎症程度，防止肠化的发生和发展。     

CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer

BACKGROUND/AIMS: Colorectal cancer is the third leading cause of cancer-related mortality in Taiwan. We became interested in searching for the factors predictive of survival. Serum CA19-9 (carbohydrate antigen 19-9) level has been reported as a factor predictive of survival in patients with colorectal cancer. A few articles have reported that patients with metastatic colorectal cancer who have normal (< or = 37 U/mL) serum CA19-9 levels survived significantly longer than those with higher serum CA19-9 levels. However, these reports are contradictory and lack definite conclusions. This study was carried out in an effort to evaluate the prognostic significance of serum CA19-9 levels in patients with metastatic colorectal cancer in Taiwan. METHODOLOGY: Between 1991 and 1994, a total of 128 patients with histologically confirmed metastatic colorectal cancers were evaluated retrospectively at Veterans General Hospital-Taipei. All patients had measurable metastatic lesions and life expectancies of more than 3 months. 5-Fluorouracil-based chemotherapy, either in a weekly bolus regimen or a monthly 5-day bolus schedule, were administered to all of them. Data on age, sex, performance status, location of primary tumor, extent of metastases, site of metastases, histological differentiation, serum CEA (carcinoembryonic antigen) and CA19-9 levels were analyzed before chemotherapy to determine their association with survival. Blood samples for CEA and CA19-9 measurement were analyzed using the radioimmunoassay method. Multivariate analysis by the Cox's proportional hazards regression model was performed to determine independent prognostic factors among all of the possible variables. RESULTS: By univariate analysis, serum CA19-9 levels (P < 0.001) and performance status of the patients (P = 0.022) were identified as prognostic factors, while age, sex, location of primary tumor, site of metastasis, histological differentiation, and pre-treatment serum CEA levels were not considered significant. By multivariate analysis, serum CA19-9 levels (P < 0.001) and performance status of the patients (P = 0.014) were still found as independent prognostic factors of these patients. CONCLUSIONS: The data from our study indicate that serum CA19-9 level is the most significant prognostic indicator of patients with metastatic colorectal cancer. It is recommended that stratification for further clinical trials for patients with metastatic colorectal cancer should be carried out according to serum CA19-9 levels.